Repligen (NASDAQ:RGEN) management said the company capped 2025 with a “great finish,” posting fourth-quarter revenue of $198 ...

Q4 2025 Management View Olivier Loeillot, President and CEO, emphasized a strong finish to 2025 with revenue of $198 million ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results , with sales up 18.1% year on ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours ...

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the ...

As of Tuesday, February 24, Repligen Corporation’s RGEN share price has dipped by 6.43%, which has investors questioning if ...

Repligen (NASDAQ:RGEN) gains attention as Nasdaq Composite capital rotation reshapes biotech supplier valuations.

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Tuesday reported fourth-quarter earnings of $13.3 million. The Waltham, Massachusetts-based company said it had net income of 23 ...

Avitide, a company that spun out of an Ivy League lab with a way to quickly and efficiently purify biologic drugs, is being acquired for $150 million by global bioprocessing vendor Repligen, which ...